查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
重度抑鬱症 (MDD) 市場-KOL 考慮、競爭趨勢、市場分析和預測 (2032)
市場調查報告書
商品編碼
1067325

重度抑鬱症 (MDD) 市場-KOL 考慮、競爭趨勢、市場分析和預測 (2032)

Major Depressive Disorder (MDD) | Primary Research (KOL's Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
出版日期: | 出版商: Mellalta Meets LLP | 英文 267 Pages | 訂單完成後即時交付

價格
簡介目錄

在研究期間（2018-2032 年），G7 國家的重度抑鬱症 (MDD) 患者總數預計到 2032 年將增加到 51,356,131 人。

估計顯示，2018 年美國患有重度抑鬱症 (MDD) 的總人數為 30,756,221 人。預計在接下來的 2032 年，它將以顯著的複合年增長率增長。在五個歐盟國家中，英國的病例數最多，其次是法國、德國、意大利和西班牙。據報導，日本的病例數僅次於美國和英國。

本報告探討了重度抑鬱症 (MDD) 市場，並概述了市場，以及重度抑鬱症的流行病學、治療趨勢、對 2032 年的預測、未滿足的需求和未來的市場前景。

目錄

執行摘要

重度抑鬱症 (MDD) 疾病的背景

  • 重度抑鬱症 (MDD) 的定義
  • 症狀和原因
  • 病理生理學
  • 診斷
    • MDD 評估工具
    • 所選抑鬱量表的詳細信息
    • 診斷標準
  • 沒有受訪者有患 TRD 的風險

到 2032 年的流行病學估計和預測

  • 主要調查結果
  • 技術和數據源
    • 按國家/地區（美國、德國、法國、意大利、西班牙、英國和日本）劃分的重度抑鬱症 (MDD) 常見病例
    • 特定國家/地區的重度抑鬱症 (MDD) 給藥案例

重度抑鬱症（MDD）流行病學和模型參數的主要來源

  • 美國
  • 德國
  • 法國
  • 意大利
  • 西班牙
  • 英國
  • 日本

當前的治療和醫療實踐

未滿足的需求

非處方治療

  • 鹽酸艾氯胺酮（強生）
    • 產品簡介
    • 臨床開發
    • 到 2032 年的銷售和市場機會

新療法

重度抑鬱症 (MDD) - 報銷方案

重度抑鬱症 (MDD) - 成本負擔和處方調查

未來治療範式

當前和新療法的年度費用

市場展望

  • 主要調查結果
  • 到 2032 年按國家/地區劃分的市場預測
    • G7 重度抑鬱症市場 (MDD)：2018-2032 年（100 萬美元）
    • G7 重度抑鬱症 (MDD) 市場：2018-2032 年（100 萬美元），按治療

各國市場預測

  • 美國
  • 德國
  • 法國
  • 意大利
  • 西班牙
  • 英國
  • 日本

市場促進因素和障礙

附錄

簡介目錄
Product Code: MM202046

Current treatment of MDD aims to fully resolve the disease-induced symptoms, to improve the quality of life and functionality in daily life. Despite advancements in MDD treatment and management options, improvements have failed to meet patient desired outcomes. Several emerging therapies such as Dextromethorphan+bupropion/AXS-05 (Axsome Therapeutics), Ansofaxine hydrochloride/LY03005 (Luye Pharma), Zuranolone/SAGE-217 (Biogen Inc./Sage Therapeutics/ Shionogi) are coming up to address the current challenges of MDD patients.

Major depressive disorder (MDD), also referred to as clinical depression, is a debilitating disease that is characterized by depressed mood, diminished interests, impaired cognitive function, and vegetative symptoms, such as disturbed sleep or appetite. MDD is associated with alterations in regional brain volumes, particularly the hippocampus, and with functional changes in brain circuits, such as the cognitive control network and the affective-salience network. Furthermore, disturbances in the main neurobiological stress-responsive systems, including the hypothalamic-pituitary-adrenal axis and the immune system, occur in MDD.

MDD is diagnosed based on the Diagnostic and Statistical Manual of Mental Disorders, or DSM-5 criteria. The patient must have at least five of the stated symptoms present during the same two-week period. One of the symptoms must include diminished interest/pleasure or depressed mood. In addition to a psychiatric evaluation, diagnosis of MDD could also include physical and/or blood tests to rule out causes for other conditions such as substance abuse, medical conditions such as diabetes and hypothyroidism, as well as other psychiatric disorders.

Major Depressive Disorder (MDD) Prevalence (Epidemiology)

The total prevalent cases in the G7 countries are anticipated to rise to 51,356,131 by 2032 for the study period (2018-2032).

Major depression is one of the most common mental disorders in the United States. According to the 1-year prevalence data published by National Survey on Drug Use and Health (NSDUH), there were approximately 19.4 million adults in the US that had at least one major depressive episode in the year 2019.

As per estimates, the United States accounted for the highest prevalence of Major Depressive Disorder (MDD) cases in 2018 which was 30,756,221 cases, and is expected to experience a significant rise by 2032 with an impressive CAGR for the study period 2018-2032. Among the EU5, the UK had the highest Major Depressive Disorder (MDD) cases, followed by France, Germany, Italy, and Spain. Japan is reported to have the highest number of cases after the United States and the UK.

Major Depressive Disorder (MDD) Current Market Size & Forecast Trends

The Major depressive disorder (MDD) therapeutics market is expected to increase at a significant rate during the forecast period i.e. 2022-2032. In the year 2022, the market is rapidly evolving and developing at a consistent rate and will depend on the strategies and vision of the major market players. The current MDD treatment market includes tricyclic antidepressants (TCA), serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and atypical antipsychotics.

The increasing prevalence of major depressive disorder, the increasing usage of antidepressants and augmentation medications will drive the MDD market. Additionally, the introduction of new therapies such as Spravato, AXS-05, LY03005, Zuranolone, REL-1017, and others will drive the market growth during the forecast period from 2022-to 2032.

Report Highlights:

  • Major Depressive Disorder (MDD) - Current Market Trends
  • Major Depressive Disorder (MDD) - Current & Forecasted Cases across the G7 Countries
  • Major Depressive Disorder (MDD) - Market Opportunities And Sales Potential for Agents
  • Major Depressive Disorder (MDD) - Patient-based Market Forecast to 2032
  • Major Depressive Disorder (MDD) - Untapped Business Opportunities
  • Major Depressive Disorder (MDD) - Product Positioning Vis-a-vis Competitors' Products
  • Major Depressive Disorder (MDD) - KOLs Insight

Table of Contents

Executive Summary

  • Key Findings

Major Depressive Disorder (MDD) Disease Background

  • Major Depressive Disorder (MDD) Definition
  • Symptoms & Causes
  • Pathophysiology
  • Diagnosis
    • MDD Assessment Tools
    • Additional Details on Selected Depression Scales
    • Diagnostic Criteria
  • Primary Nonresponders Are at Risk of Developing TRD

Epidemiology Estimated and Forecast to 2032

  • Key Findings
  • Methods and Data Sources
    • Country Specific Prevalent cases of Major Depressive Disorder (MDD) (US, Germany, France, Italy, Spain, UK, and Japan)
    • Country Specific Drug Treated Cases of Major Depressive Disorder (MDD)

Key Sources for Major Depressive Disorder (MDD) Epidemiology and Model Parameters

  • The United States
    • The United States Prevalent cases of Major Depressive Disorder (MDD)
    • United States Drug Treated Cases of Major Depressive Disorder (MDD)
  • Germany
    • Germany Prevalent cases of Major Depressive Disorder (MDD)
    • Germany Drug Treated Cases of Major Depressive Disorder (MDD)
  • France
    • France Prevalent cases of Major Depressive Disorder (MDD)
    • France Drug Treated Cases of Major Depressive Disorder (MDD)
  • Italy
    • Italy Prevalent cases of Major Depressive Disorder (MDD)
    • Italy Drug Treated Cases of Major Depressive Disorder (MDD)
  • Spain
    • Spain Prevalent cases of Major Depressive Disorder (MDD)
    • Spain Drug Treated Cases of Major Depressive Disorder (MDD)
  • The United Kingdom
    • United Kingdom Prevalent cases of Major Depressive Disorder (MDD)
    • United Kingdom Drug Treated Cases of Major Depressive Disorder (MDD)
  • Japan
    • Japan Prevalent cases of Major Depressive Disorder (MDD)
    • Japan Drug Treated Cases of Major Depressive Disorder (MDD)

Current Therapies and Medical Practice

  • Treatments & Medical Practices
  • Potential Treatment Guidelines/Algorithms
  • Clinical Guidelines for the Treatment of Depression
  • Dosing of medications shown to be effective In treating Major Depressive Disorder (MDD)
  • Marketed treatment for Major Depressive Disorder (MDD)
  • Potential treatments for side effects of antidepressant medications in Major Depressive Disorder (MDD)

Unmet Needs

Marketed Therapies

  • Esketamine hydrochloride (Johnson & Johnson)
    • Product Profile
    • Clinical Development
    • Sales & Market Opportunity by 2032

Emerging Therapies

  • Pipeline Overview
  • Therapeutic Developments Pipeline for Major Depressive Disorder (MDD)
    • Product Analysis
  • AXS-05 (Axsome Therapeutics Inc.)
    • Product Profile
    • Clinical Development
    • Sales & Market Opportunity by 2032
  • LY03005 (Luye Pharma)
    • Product Profile
    • Clinical Development
    • Sales & Market Opportunity by 2032
  • Zuranolone (Biogen Inc./Sage Therapeutics/Shionogi)
    • Product Profile
    • Clinical Development
    • Sales & Market Opportunity by 2032
  • Cariprazine (Gedeon Richter Plc./Abbvie)
    • Product Profile
    • Clinical Development
    • Sales & Market Opportunity by 2032
  • Caplyta (Intra-Cellular Therapies Inc.)
    • Product Profile
    • Clinical Development
    • Sales & Market Opportunity by 2032
  • REL-1017 (Relmada Therapeutics Inc.)
    • Product Profile
    • Clinical Development
    • Sales & Market Opportunity by 2032
  • Seltorexant (Minerva Neurosciences/Janssen/Royalty Pharma)
    • Product Profile
    • Clinical Development
    • Sales & Market Opportunity by 2032
  • PRAX-114 (Praxis Precision Medicines Inc.)
    • Product Profile
    • Clinical Development
  • SPL026 (Small Pharma)
    • Product Profile
    • Clinical Development
  • SLS-002 (Seelos Therapeutics Inc.)
    • Product Profile
    • Clinical Development
  • Psilocybin (Usona Institute/The Emmes Company/Signant Health)
    • Product Profile
    • Clinical Development
  • PH10 (Pherin Pharmaceuticals/VistaGen Therapeutics)
    • Product Profile
  • AV-101 (VistaGen Therapeutics Inc.)
    • Product Profile
    • Clinical Development
  • Other Emerging Drugs For Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD)- Reimbursement Scenario

Major Depressive Disorder (MDD)- Cost Burden & Prescriptions survey

Future Treatment Paradigm

  • Major Depressive Disorder (MDD) Competitor Landscape and Approvals Anticipated
  • Future Treatment Algorithms and Competitor Positioning
  • Key Data Summary for Emerging Treatment

Annual Cost of Current & Emerging Therapies

Market Outlook

  • Key Findings
  • Country-Specific Market Forecast to 2032
    • G7 total Market for Major Depressive Disorder (MDD) 2018-2032 (USD Million)
    • G7 total Market for Major Depressive Disorder (MDD) by Therapies 2018-2032 (USD Million)

Market Forecast by Country

  • The United States
    • United States Market for Major Depressive Disorder (MDD) 2018-2032 (USD Million)
    • United States Market for Major Depressive Disorder (MDD) by Therapies 2018-2032 (USD Million)
  • Germany
    • Germany Market for Major Depressive Disorder (MDD) 2018-2032 (USD Million)
    • Germany Market for Major Depressive Disorder (MDD) by Therapies 2018-2032 (USD Million)
  • France
    • France Market for Major Depressive Disorder (MDD) 2018-2032 (USD Million)
    • France Market for Major Depressive Disorder (MDD) by Therapies 2018-2032 (USD Million)
  • Italy
    • Italy Market for Major Depressive Disorder (MDD) 2018-2032 (USD Million)
    • Italy Market for Major Depressive Disorder (MDD) by Therapies 2018-2032 (USD Million)
  • Spain
    • Spain Market for Major Depressive Disorder (MDD) 2018-2032 (USD Million)
    • Spain Market for Major Depressive Disorder (MDD) by Therapies 2018-2032 (USD Million)
  • The United Kingdom
    • United Kingdom Market for Major Depressive Disorder (MDD) 2018-2032 (USD Million)
    • United Kingdom Market for Major Depressive Disorder (MDD) by Therapies 2018-2032 (USD Million)
  • Japan
    • Japan Market for Major Depressive Disorder (MDD) 2018-2032 (USD Million)
    • Japan Market for Major Depressive Disorder (MDD) by Therapies 2018-2032 (USD Million)

Market Drivers and Constraints

  • What Factors Are Driving the Market for Major Depressive Disorder (MDD)?
  • What Factors Are Constraining the Market for Major Depressive Disorder (MDD)?

Appendix

  • About Mellalta Meets